Navigation Links
Landscape for Lung Cancer Therapies is Focus of New Post-ASCO MedPredict Report
Date:6/26/2008

SCOTTSDALE, Ariz., June 26 /PRNewswire/ -- MedPredict has published a new report in its oncology series entitled "Thought Leader Insight & Analysis: Lung Cancer," designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in non-small cell and small cell lung cancer.

The big news at the recent American Society of Clinical Oncology (ASCO) meeting was the presentation of the Erbitux FLEX clinical trial data showing increased overall survival in EGFR-positive first-line non-small cell lung cancer. In light of these positive results, MedPredict's panel addresses the following questions: Is Erbitux useful in those 40% of patients who are Avastin-ineligible? Is Erbitux useful in the 24% patients who aren't getting Avastin but in theory could? Is Erbitux going to legitimately threaten Avastin in an Avastin-eligible patient?

MedPredict's panel also reviews recent advances in other mechanistic approaches to treatment, including angiogenesis/VEGF, vascular disrupting agents, anthracyclines, TRAIL / DR4 / DR5, Bcl-2/Bcl-xL, survivin, cyclin dependent kinase, cMET, EGFR (T790M), antifolate, HDAC / epigenetics, Hedgehog, HSP90, IGF-1, MAGE-A3, MEK, microtubule, apoptosis, kinesin/EG5, aurora kinase, Polo-like kinase 1, mTOR, PI3/AKT, KRAS, and topoisomerase.

"This report will provide essential strategic insight for those involved in development of lung cancer therapies," according to MedPredict President Dr. Jeffrey Berk. "Our panelists discuss ongoing clinical programs, and offer their opinions on which of the myriad new drugs in development are likely to be significant improvements over current options."

Some of the companies/partnerships discussed in this report include: Abbott, Abraxis, Amgen, Angiogene, Antisoma, Ardea, Array, Ascenta, AstraZeneca, Bayer-Schering, Bristol-Myers Squibb, Boehringer Ingelheim, Concordia, Critical Outcome Technologies, Cytokinetics, Daiichi Sankyo, Eisai, Epicept, Exelixis, Genentech, GlaxoSmithKline, Human Genome Sciences, ImClone, Infinity, Lilly, Medimmune, Merck, Merck Serono, Nerviano, Novartis, Oncothyreon, OSI Pharmaceuticals, Piramed, Pfizer, Prolexys, Regeneron, Roche, Sanofi-Aventis, Semafore, Vertex.

The full report can be purchased by contacting MedPredict.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Avastin(R) Shows Unprecedented Benefits in Colorectal Cancer Patients, Irrespective of K-Ras Gene Mutation
2. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
3. Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer
4. First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies
5. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
6. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
7. New Australian Technology: Detecting Breast Cancer With Hair
8. GeneGo is Awarded NCI Grant for Development of Systems Biology Platform for Integrative Data Analysis in Cancer
9. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
10. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
11. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Volumes: Global Analysis (United States, China, Japan, Brazil, United ... to their offering. ... healthcare business planners, provides surgical procedure volume data in ... with an in-depth analysis of growth drivers and inhibitors, ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its ... Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding ... Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, we ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
(Date:6/24/2016)... MD (PRWEB) , ... June 24, 2016 , ... ... protocols for human induced pluripotent stem (iPS) cells and other difficult to transfect ... G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is a ...
Breaking Medicine News(10 mins):